In this preview of the 2023 Community Oncology Conference, past president of the Community Oncology Alliance, David Eagle, MD, of New York Cancer & Blood Specialists, discusses what has him excited for this year's meeting, both sessions and speakers.
Exciting happenings at the upcoming Community Oncology Conference include the attendance of several past presidents of the Community Oncology Alliance (COA), as well as sessions on the Enhancing Oncology Model and pharmacy benefit managers, according to David Eagle, MD, chair of legislative affairs and patient advocacy at New York Cancer & Blood Specialists, COA executive committee member, and past COA president.
Transcript
What speakers and sessions have you excited to attend this year’s Community Oncology Conference?
I’m excited that COA has now turned 20 years old. I think a new oncology organization gets born about once every generation, and so we’re proud that we’ve been around for 20 years now. We’ve got a few of the past presidents coming in for the event.
I am excited about the Enhancing Oncology Model sessions, because I think as we get to March, there’s going to be a lot of tension in terms of where we are with practices deciding whether to enroll in the Enhancing Oncology Model. I think we’re kind of in a tricky time for that. We’ll be figuring out very soon thereafter whether it makes sense for a practice to enroll.
I’m looking forward to the sessions on pharmacy benefit managers as well. That’s certainly an area that affects patients and practices as well—along with the future of oncology, which, honestly, I don’t know the answer to, so I’m looking forward to hearing about what the future of oncology is going to be.
New Insights on Breast Cancer Outcomes Among Sexual, Gender Minorities
December 7th 2023Despite there being a great demand for data collection on sexual orientation and gender identity in the cancer space, individuals who identify as a sexual and gender minority remain poorly represented.
Read More
Exagamglogene Autotemcel Meets End Points in Severe Sickle Cell Disease, β-Thalassemia
December 7th 2023Two posters set to be presented at the 65th American Society of Hematology Annual Meeting & Exposition met their primary and secondary end points regarding exagamglogene autotemcel therapy for sickle cell disease and β-thalassemia.
Read More
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
Race/Ethnicity May Influence Local Recurrence in DCIS, Adjuvant Treatment
December 6th 2023Disparities in 10-year local recurrence following breast-conserving surgery were seen among women with ductal carcinoma in situ (DCIS) treated over a nearly 4-decade span at Memorial Sloan Kettering Cancer Center, with Black women having the highest rate.
Read More
SDOH in Cancer Care Highlight Multifactorial Equity Issues
December 6th 2023A trio of speakers addressed the importance of social determinants of health (SDOH) in cancer care on day 1 of the 46th annual San Antonio Breast Cancer Symposium in the session, “Social Determinants of Health: Impact on Cancer Care.”
Read More